Videos

An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

There are some key discussions that men with metastatic prostate cancer should have with their health care providers.

Researchers should not give up hope in using immunotherapy to treat brain cancers.

As the number of patients and survivors continues to increase, it is important that clinician burnout is handled appropriately, explains Thomas A. Gallo.

It is important that advocacy organizations unify their message, says Mike Crosby, the founder of the Veterans Prostate Cancer Awareness group.

Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.

By getting their tumor genetically tested, a patient may find out that they are eligible for certain treatment options.

As cancer survivors are living longer thanks to new treatments, it is essential that health care providers and researchers put more focus on depression.

Over the past few decades, prostate cancer has become better understood and treated more effectively.

The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.

A lack of vitamin D can have major impacts on myeloma treatment outomes.

The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.

The Leukemia & Lymphoma Society's (LLS) Clinical Trial Support Center helps patients with blood cancers find clinical trials that are right for them.

After finding out she had an MPN, Barbara Abernathy, Ph.D., like many other people, felt numb. But then it was time to find her fight mode.

Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.

While there is no test, such as a mamogram or colonoscopy, for uterine cancer, vaginal bleeding is a telltale sign of the disease.

It is important that patients and their loved ones stay hopeful during the ovarian cancer journey. We asked attendees of the 2018 NOCC Annual Conference how they keep positive.

Many patients with ovarian cancer have misconceptions about the care they will receive while on a clinical trial, according to Laurel W. Rice, M.D.

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

When asked about her favorite thing about Thea's Star of Hope, the ten-year-old explained that the organization is like a laser on pediatric brain tumors, shooting at them until, hopefully one day, poof! They disappear.

Jaron Mark, M.D., a gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses the opioid crisis, and the steps that his institution is taking to combat potential addiction in women who undergo surgery for gynecologic cancer.

PARP inhibitors are generating a lot of excitement in the field of ovarian cancer. But how, exactly, do they work? CURE spoke with one expert to find out.